Precautionary batch recall as a glass splinter was discovered in a 60 ml bottle.

Recall due to possible contamination with glass splinters

Up-to-date information from the February 27.03.-30.03.2024 meeting on new approvals, extensions of indication, newly published EPAR's and recently started procedures.

Recall due to appearance of the solution

Recall due to a possible incorrect closure of the crimp caps

Recall due to a possible incorrect closure of the crimp caps

This issue of RMS NEWS again contains current and relevant news for our applicants for marketing authorisations with Austria as RMS.

All ongoing clinical trials need to be converted to Clinical Trials Information System ("CTIS") in accordance with Regulation (EU) 536/2014 ("CTR") by January 31, 2025. This date marks the end of a three-year transition period that began when the CTR came into force in the EU. Clinical trials that are not converted by the sponsor in time lose their legal basis and will have to be terminated by the National authority.

The committee on herbal medicinal products (HMPC) of the European Medicines Agency (EMA) published the revised Public Statement on the use of herbal medicinal products1 containing estragole.

Recall of a batch due to visible crystalline particles